This inventor holds 1 USPTO granted patent and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Teva Pharmaceutical Industries Limited. Active years: 2007.
Company Filing History:
Years Active: 2007
Title: Esmira Naftali: Innovator in Pharmaceutical Formulations
Introduction
Esmira Naftali is a notable inventor based in Israel, recognized for her contributions to the field of pharmaceutical formulations. Her work primarily focuses on developing innovative treatments for systemic lupus erythematosus (SLE), a complex autoimmune disease.
Latest Patents
Esmira Naftali holds a patent for "Parenteral Formulations Of Peptides For The Treatment Of Systemic Lupus Erythematosus." This invention provides a pharmaceutical composition that includes an aqueous carrier and a pharmaceutically acceptable salt of a peptide. The peptide comprises a sequence of amino acids found within a complementarity-determining region of human monoclonal antibodies. The composition aims to alleviate symptoms of SLE in humans by administering an effective amount of the formulation.
Career Highlights
Esmira is associated with Yeda Research and Development Co. Ltd., where she has made significant strides in her research. Despite having no patents to her name, her work in developing peptide formulations showcases her dedication to advancing medical science and improving patient outcomes.
Collaborations
Esmira collaborates with esteemed colleagues, including Sharon Cohen-Vered and Vera Weinstein. These partnerships enhance her research efforts and contribute to the innovative environment at Yeda Research and Development Co. Ltd.
Conclusion
Esmira Naftali's work exemplifies the spirit of innovation in the pharmaceutical industry, particularly in the treatment of systemic lupus erythematosus. Her contributions, although currently limited in patent count, reflect a commitment to improving healthcare through scientific research and collaboration.